AstraZeneca Results Presentation Deck
CVRM: treating underlying conditions
Broad portfolio of next-generation medicines
Cardiovascular
AZD8233 (PCSK9¹)
hypercholesterolaemia.
MEDI6570 (LOX-1²)
CV disease
AZD8601 (VEGF-A³)
CV disease
Heart failure
No
AZD4831 (MPO4)
HFPEF5
Farxiga + AZD9977 (MCR6)
HF, CKD
●
Renal
G₁S
Farxiga (SGLT2)
CKD
Farxiga + zibotentan (ERA)
CKD
AZD5718 (FLAP8)
CAD/CKD
Metabolism
Liver disease
Q
cotadutide (GLP-19/glucagon)
NASH ¹0, DKD¹1
AZD2693 (PNPLA3¹²)
NASH
Visit astrazeneca.com for a replay of the 'Meet AZN management: BioPharmaceuticals' event
1. Proprotein convertase subtilisin/kexin type 9 2. Lectin-like oxidized low-density lipoprotein receptor-1 3. Vascular endothelial growth factor A 4. Myeloperoxidase 5. Heart failure with preserved ejection fraction 6. Mineralocorticoid receptor
7. Endothelin receptor antagonist 8. 5-Lipoxygenase-activating protein 9. Glucagon-like peptide-1 10. Non-alcoholic steatohepatitis 11. Diabetic kidney disease 12. Patatin-like phospholipase domain-containing protein.
28
3View entire presentation